Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Progenics Pharmaceuticals (PGNX)

Progenics Pharmaceuticals (PGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Progenics Pharmaceuticals ONE WORLD TRADE CENTER 47TH FLOOR NEW YORK NY 10007 USA

www.progenics.com P: 646-975-2500

Description:

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.

Key Statistics

Overview:

Market Capitalization, $K 355,048
Shares Outstanding, K 86,597
Annual Sales, $ 34,990 K
Annual Net Income, $ -68,550 K
Last Quarter Sales, $ 6,250 K
Last Quarter Net Income, $ -16,800 K
60-Month Beta 1.89
% of Insider Shareholders 4.26%
% of Institutional Shareholders 70.96%
Float, K 82,908
% Float 95.74%

Growth:

1-Year Return -15.98%
3-Year Return -45.41%
5-Year Return -39.79%
5-Year Revenue Growth -21.16%
5-Year Earnings Growth -1,433.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 08/14/20
Earnings Per Share ttm -0.77
EPS Growth vs. Prev Qtr -46.15%
EPS Growth vs. Prev Year 13.64%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

PGNX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -129.46%
Return-on-Assets % -53.23%
Profit Margin % -195.91%
Debt/Equity 0.99
Price/Sales 11.20
Price/Cash Flow N/A
Price/Book 11.60
Book Value/Share 0.35
Interest Coverage -27.80
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar